? In Support of Research for Treating the 4 Million Canadians
Who Have Chronic Kidney Disease Today ?
CALGARY, Alberta, Sept. 07, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation September 8th through 10th, in the Kidney Foundation's "Kidney March", in support of the almost 4 million Canadians who have chronic kidney disease today.
The Company is pleased to participate in this important annual event which supports fund raising to further basic kidney research, and to join the kidney disease support community. This year XORTX has committed to support the Kidney March through sponsorship of Sunday "Kidney March" events and closing ceremonies of the "Kidney March". Details on the Kidney Foundation and the Kidney March are included in the following links - https://kidney.ca/ and https://kidneymarch.ca/basics/
Dr. Allen Davidoff, XORTX's CEO stated, "Our efforts this week in support of the Kidney Foundation of Canada is a small contribution, to address a much larger, growing, global problem. It is notable that kidney disease is estimated to affect almost 1 in 7 individuals and because symptoms are few, diagnosis often occurs in mid to late stage of disease. More concerning is an estimated rate of new chronic kidney disease that exceeds 10% per year and doubling the number of cases ...